Abstract
The Seventh International Symposium on graft-versus-host and graft-versus-leukemia reactions was held in Garmisch Partenkirchen (Germany, near Lake Riessersee) between January 22nd and 25th, 2006. A total of more than 100 invited participants (scientists and clinicians working in the area of allogeneic stem cell transplantation) discussed research in the area of lymphoid malignancies. Major topics of the 2006 meeting were lymphocyte biology, experimental systems, lymphoma pathogenesis, cellular therapy in vivo and vitro, idiotype-specific responses and graft-versus-malignancy reactions for lymphomas and multiple myeloma. Further highlights were immune responses to blasts of ALL, haploidentical transplantation, role of natural killer cells, clinical guidelines for allogeneic transplantation and adoptive immunotherapy in chronic lymphocytic leukemia and multiple myeloma, new antibody-mediated strategies. As can be seen in the summaries of the individual presentations, progress was made in the understanding of lymphoma biology and in the clinical application of graft-versus-lymphoma or graft-versus-myeloma effects. Each day was followed by round-table discussions, which summarized new data and challenged established concepts. The discussions resulted in new insights and projects for basic research and clinical transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Boehm T, Hofer S, Winklehner P, Kellersch B, Geiger C, Trockenbacher A et al. Attenuation of cell adhesion in lymphocytes is regulated by CYTIP, a protein which mediates signal complex sequestration. EMBO J 2003; 22: 1014–1024.
Hofer S, Pfeil K, Niederegger H, Ebner S, Nguyen VA, Kremmer E et al. Dendritic cells regulate T-cell deattachment through the integrin-interacting protein CYTIP. Blood 2006; 107: 1003–1009.
Stevenson FK, Rice J, Ottensmeier CH, Thirdborough SM, Zhu D . DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunol Rev 2004; 199: 156–180.
Rice J, Buchan S, Dewchand H, Simpson E, Stevenson FK . DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. J Immunol 2004; 173: 4492–4499.
Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J . Electroporation as a ‘Prime/Boost’ strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005; 174: 6292–6298.
Adler H, Messerle M, Wagner M, Koszinowski UH . Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol 2000; 74: 6964–6974.
Adler H, Messerle M, Koszinowski UH . Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences. J Virol 2001; 75: 5692–5696.
Adler H, Messerle M, Koszinowski UH . Cloning of herpesviral genomes as bacterial artificial chromosomes. Rev Med Virol 2003; 13: 111–121.
Küppers R . Mechanisms of B cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251–262.
Bechtel D, Kurth J, Unkel C, Küppers R . Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphoma. Blood 2005; 106: 4345–4350.
Bräuninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Küppers R . Molecular biology of Hodgkin and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006; 118: 1853–1861.
Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A et al. Cytotoxic T lymphocyte therapy for Epstein–Barr virus+ Hodgkin's disease. J Exp Med 2004; 200: 1623–1633.
Gottschalk S, Heslop H, Rooney C . Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005; 46: 1–10.
Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005; 106: 4389–4396.
Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000; 6: 667–672.
Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res 2006; 66: 4496–4502.
Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051–3057.
Imai C, Iwamoto S, Campana D . Genetic modification of primary natural killer cells overcomes inhibitory cells and induces specific killing of leukemic cells. Blood 2005; 106: 376–383.
Kröger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755–760.
Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129: 631–643.
Kröger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: 3361–3363.
Ayuk F, Fang L, Fehse B, Zander AR, Kröger N . Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol 2005; 33: 1531–1536.
Jedema I, Van der Werff NM, Barge RMY, Willemze R, Falkenburg JH . New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004; 103: 2677–2682.
Hoogendoorn M, Olde Wolbers J, Smit WM, Schaafsma MR, Barge RM, Willemze R et al. Generation of B cell chronic lymphocytic leukemia (B-CLL)-reactive T cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia 2004; 18: 1278–1287.
Hoogendoorn M, Olde Wolbers J, Smit WM, Jedema I, Barge RM, Willemze R et al. Primary allogeneic T cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation. Clin Cancer Res 2005; 15: 5310–5318.
Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P et al. Determinants of antileukemic effects of allogeneic NK cells. J Immunol 2004; 172: 644–650.
Lang P, Barbin K, Feuchtinger T, Greil J, Peipp M, Zunino SJ et al. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blast with effector cells from pediatric patients who received T-cell-depleted allografts. Blood 2004; 103: 3982–3985.
Leung W, Iyengar R, Triplett B, Turner V, Behm FG et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immun 2005; 174: 6540–6545.
Kolb HJ, Schmid C, Barrett AJ, Schendel DJ . Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767–776.
Munker R, Schmid C, Madrigal JA, Kolb HJ . An update on graft-versus-host and graft-versus-leukemia reactions: a summary of the sixth international symposium held in Schloss Ellmau, Germany 22–24, 2004. Bone Marrow Transplant 2004; 34: 767–780.
Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563–4569.
Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Int Med 1996; 124: 311–315.
Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753.
Hallek M . Chemoimmunotherapy – towards real progress in the treatment of chronic lymphocytic leukemia. Nat Clin Pract Oncol 2005; 2: 338–339.
Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M et al. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 2005; 105: 1566–1573.
Mayr C, Kofler DM, Buning H, Bund D, Hallek M, Wendtner CM . Transduction of CLL cells by CD40 ligand (CD40L) enhances an antigen specific immune recognition by autologous T cells. Blood 2005; 106: 3223–3226.
Lux K, Goerlitz N, Schlemminger S, Perabo L, Goldnau D, Endell J et al. GFP-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J Virol 2005; 79: 11776–11787.
Seisenberger G, Ried MU, Endress T, Buning H, Hallek M et al. Real-time single molecule imaging of the infection pathway of an adeno-associated virus. Science 2001; 294: 1929–1932.
Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J et al. Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2 (AAV2). Nat Med 1999; 5: 1052–1056.
Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S . Use of trifunctional bispecific antibodies to prevent graft-versus host disease induced by allogeneic lymphocytes. Blood 2006; 107: 1564–1569.
Arditti FD, Aviner S, Dekel B, Krautgamer R, Gan J, Nagler A et al. Eradication of B-CLL by autologous and allogeneic host nonreactive anti-third party CTLs. Blood 2005; 105: 3365–3371.
Pedersen AE, Skov S, Bregenholt S, Ruhwald M, Claesson MH . Signal transduction by the major histocompatibility class I molecule. APMIS 1999; 107: 887–895.
Collin MP, Hart DN, Jackson GH, Cook G, Cavet J, Mackinnon S et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med 2006; 203: 27–33.
Acknowledgements
This year's symposium (‘Tolerance and Immunity’) was jointly organized by the Ludwigs-Maximilians-University of Munich (Sonderforschungsbereich 455), GSF (National Research Center for Environment and Health), Stiftung Aktion Knochenmarkspende Bayern and supported by Deutsche José Carreras Leukämie Stiftung. The organizers and authors of the conference proceedings would again like to extend their gratitude to all participants for sharing their ideas, slides and manuscripts and making this event possible.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Munker, R., Reibke, R. & Kolb, H. Graft-versus-host and graft-versus-leukemia reactions: a summary of the Seventh International Symposium held in Garmisch-Partenkirchen, Germany, February 22nd–25th, 2006, Tolerance and Immunity, an update on lymphoid malignancies. Bone Marrow Transplant 38, 593–607 (2006). https://doi.org/10.1038/sj.bmt.1705499
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705499
Keywords
This article is cited by
-
ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34/CD133 selected or CD3/CD19 depleted stem cells, DLI and purified CD56+CD3− NK cells
International Journal of Hematology (2008)
-
Graft-versus-leukemia in chronic lymphocytic leukemia
Bone Marrow Transplantation (2007)